Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.23 USD
Change Today -0.0009 / -0.39%
Volume 971.0K
ELTP On Other Exchanges
As of 8:10 PM 05/5/15 All times are local (Market data is delayed by at least 15 minutes).

elite pharmaceuticals inc (ELTP) Snapshot

Previous Close
Day High
Day Low
52 Week High
05/14/14 - $0.47
52 Week Low
12/1/14 - $0.17
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

elite pharmaceuticals inc (ELTP) Related Businessweek News

No Related Businessweek News Found

elite pharmaceuticals inc (ELTP) Details

Elite Pharmaceuticals, Inc., a specialty pharmaceutical company, principally engaged in the research, development, and licensing of proprietary controlled-release drug delivery systems and products. The company develops orally administered controlled-release products for various therapeutic areas, including pain, allergy, and infection. It owns, licenses, sells, and contract manufactures Phentermine tablets and capsules, Lodrane D Immediate Release capsules, Methadone tablets, Hydromorphone Hydrochloride tablets, Phendimetrazine tartrate tablets, and Naltrexone HCl tablets. The company also has a pipeline of other generic drug candidates under development; and is developing abuse resistant opioid products and once-daily opioid products. In addition, it is engaged in contract research and development on behalf of other pharmaceutical companies. The company has strategic alliance agreements with Epic Pharma, LLC and Epic Investments, LLC. Elite Pharmaceuticals, Inc. was founded in 1984 and is headquartered in Northvale, New Jersey.

38 Employees
Last Reported Date: 06/30/14
Founded in 1984

elite pharmaceuticals inc (ELTP) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $378.1K
Chief Financial Officer, Chief Accounting Off...
Total Annual Compensation: $161.3K
Head of Development
Total Annual Compensation: $32.4K
Compensation as of Fiscal Year 2014.

elite pharmaceuticals inc (ELTP) Key Developments

Elite Pharmaceuticals Announces Launch of Generic Hydroxyzine Tablets

Elite Pharmaceuticals, Inc. announced the launch of generic Hydroxyzine HCI 10 mg, 25 mg and 50 mg tablets through Epic Pharma LLC. Hydroxyzine is indicated for symptomatic relief of anxiety and tension associated with certain disease states and management of pruritus due to certain allergic conditions. Annual U.S. sales for immediate release Hydroxyzine HCI 10 mg and 25 mg and 50 mg tablets are approximately $40 million for the twelve months ending June 30, 2014 according to IMS Health Data. Epic will manufacture, package and distribute the product under the Manufacturing and License Agreement previously signed between Epic and Elite. Elite also announced that dosing was completed for two studies to support ELI-200 product labeling - the fed study and the withdrawal effects study. The first study is a Phase I, open-label, randomized, single-dose, three-way crossover study to compare the bioavailability of ELI-200 to the reference product under fed conditions in healthy volunteers. The second study, a safety study, is a randomized, double-blind, multiple-dose, parallel group study to evaluate the potential withdrawal effects following administration of ELI-200 versus the reference product in methadone-maintained opioid-dependent subjects. Final study results are not yet available. A Phase III efficacy study is scheduled to begin dosing this quarter. This Phase III study is a multi-center, randomized, multiple-dose, blinded, placebo-controlled, parallel group, study to evaluate the efficacy and safety of abuse deterrent ELI-200 for the treatment of adults with moderate to severe pain following surgery. The study will enroll approximately 165 patients at five clinical sites and will begin once final FDA agreement is received for the protocol. The company expects the study to begin in approximately 7 weeks and the dosing for the study to take approximately 8 weeks.

Elite Pharmaceuticals, Inc. Announces Consolidated Revenue Results for the Third Quarter and Nine Months Ended December 31, 2014

Elite Pharmaceuticals, Inc. announced consolidated revenue results for the third quarter and nine months ended December 31, 2014. Consolidated revenues for the third quarter of fiscal 2015 continued their upward trend, rising to $1.4 million, an increase of approximately 8.5% over consolidated revenues for the second quarter of fiscal 2015. The third quarter revenues for this year were $0.3 million below revenues reported for the third quarter of the prior fiscal year due to a one-time $0.6 million milestone that occurred in the prior year third quarter. Revenues for the nine months ending December 31, 2014 were $3.8 million, an increase of 6% over revenues for the comparable period of the prior year, even with the one-time milestone being included in the prior year revenues. The increase in revenues is due to the continued growth and expansion of Elite’s generic product lines.

Elite Pharmaceuticals, Inc., Q3 2015 Earnings Call, Feb 18, 2015

Elite Pharmaceuticals, Inc., Q3 2015 Earnings Call, Feb 18, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ELTP:US $0.23 USD -0.0009

ELTP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alkermes PLC $55.74 USD -1.87
Durect Corp $2.29 USD -0.04
Egalet Corp $8.87 USD -0.46
Nektar Therapeutics $11.17 USD -0.17
Zogenix Inc $1.40 USD -0.08
View Industry Companies

Industry Analysis


Industry Average

Valuation ELTP Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 28.6x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 20.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ELITE PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at